Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015260 | 0.91 | SIRT2 (0.40) | SIRT2SIRT1SIRT5SIRT3MMP3 | |
| SCHEMBL14015259 | 0.86 | FOLH1 (0.43) | — | |
| SCHEMBL14014263 | 0.75 | TDP1 (0.52) | — | |
| SCHEMBL14014269 | 0.74 | FOLH1 (0.44) | — | |
| SCHEMBL12567137 | 0.73 | SIRT2 (0.44) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL12285414 | 0.73 | PSMB8 (0.47) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL5307097 | 0.72 | PTGER4 (0.56) | SIRT5 | |
| SCHEMBL6013148 | 0.71 | SIRT2 (0.47) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL30471718 | 0.71 | SSTR3 (0.50) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL5550452 | 0.71 | SIRT2 (0.45) | SIRT2SIRT1SIRT5SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | SIRT2 1084/4885SIRT1 319/4885SIRT5 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.